03:37 PM EST, 02/13/2025 (MT Newswires) -- ImmunityBio ( IBRX ) said Thursday that the UK's Medicines and Healthcare Products Regulatory Agency accepted its marketing authorization application for Anktiva in combination with bacillus Calmette-Guerin to treat certain patients with non-muscle invasive bladder cancer.

The application covers patients who do not respond to bacillus Calmette-Guerin and are with carcinoma in situ with or without papillary tumors, the company said.

Shares of the company were up 2.8% in recent trading.

Price: 3.33, Change: +0.09, Percent Change: +2.81